子宫内膜异位症患者血清CA125测定

子宫内膜异位症患者血清ＣＡ＿（１２５）测定熊晓燕，舒明炎，高晓秋，刘惠兰，丛克家目前，子宫内膜异位症的诊断，主要依靠临床症状、体征及腹腔镜所见，而缺乏特异性手段。近年来研究发现，子宫内膜异位症患者血清ＣＡ＿（１２５）升高￣［１］。本研究对１１６例开腹...     

血清CA125与抗子宫内膜抗体联合测定对子宫内膜异位症的诊断价值

目的 探讨血清CA125与抗子宫内膜抗体联合测定对于宫内膜异位症诊断的临床价值。方法 应用放射免疫法及酶联免疫吸附试验（ELISA）法测定44例子宫内膜异位症患者（EMT组）血清中CA125值及EMAb阳性情况，并与40例健康妇女对照组进行比较。结果 EMT组血清CA125值阳性率为61．4％（27／44），显著高于对照组5．0％（2／40），P〈0．05；EMT组抗子宫内膜抗体阳性率为65．9％（29／44），显著高于对照组7．5％（3／40），P〈0．05；联合测定EMT患者血清CA125值及抗子宫内膜抗体，其敏感性明显高于两者单独测定的敏感性。结论 血清CA125与抗子宫内膜抗体联合测定可提高子宫内膜异位症诊断的敏感性。     

子宫内膜异位症患者血清CA125,抗子宫内膜抗体的测定

子宫内膜异位症患者血清ＣＡ１２５、抗子宫内膜抗体的测定伍俊萍张惜阴子宫内膜异位症是生育年龄妇女的常见病，我们测定子宫内膜异位症患者血清ＣＡ１２５、抗子宫内膜抗体（ＥｍＡｂ）的水平，并探讨其诊断价值。一、资料与方法１．研究对象：从我院１９９３年１２月至...     

联合测定血清EMAb和CA125对子宫内膜异位症的诊断价值

子宫内膜异位症 (ｅｎｄｏｍｅｔｒｉｏｓｉｓ ,ＥＭＴ)多见于生育期妇女 ,是引起下腹部疼痛的主要原因之一 ,其发病率各家报道不一 ,变化于 1%～ 5 0 %之间[1] 。腹腔镜是目前诊断ＥＭＴ的金标准 ,至今尚无一种简单有效的非损伤性的诊断方法 ,本文通过联合测定血清抗子宫内膜抗体 (ＥＭＡｂ)和ＣＡ12 5水平 ,以期为ＥＭＴ诊断提供一条新途径。1　资料与方法1 1　研究对象ＥＭＴ患者 34例 (ＥＭＴ组 ) ,年龄 2 1～ 4 6岁 ,平均为33 6岁 ,均为 1999年 11月至 2 0 0 1年 1月在我院妇科经手术病理诊断为ＥＭＴ住院患者。按修订的美国生育学会(…     

子宫内膜异位症患者血清中抗子宫内膜IgG抗体及CA125的测定

子宫内膜异位症 (内异症 )近年已成为一种严重影响育龄妇女生存质量的常见病。腹腔镜可早期诊断 ,但它是一种创伤性操作 ,费用高。为寻求简便、易行、无创性诊断方法 ,我们对内异症患者、正常及良性疾病对照者血清中的抗子宫内膜ＩｇＧ抗体及ＣＡ12 5值进行了测定 ,并探讨其用于临床诊断内异症的意义。一、资料和方法1.研究对象 :为 1998年 8月至 1999年 10月在我院住院经腹腔镜和开腹手术及病理检查证实为内异症的 39例患者 ,按 1985年美国生育协会修正的内异症分期法 (ＲＡＦＳ)进行分期 ,Ⅰ、Ⅱ期 8例 ,Ⅲ期 16例 ,Ⅳ期 15例 ;对照组 5 2…     

血清及腹腔液CA125测定对子宫腺肌病的诊断价值

目的探讨血清及腹腔液CA125测定对子宫腺肌病的诊断价值.方法采用免疫化学发光法测定28例子宫腺肌病和25例子宫肌瘤患者血清及腹腔液(110稀释)CA125水平.结果子宫腺肌病患者血清CA125水平高于子宫肌瘤患者,差异有显著性(P＜0.01).两组间腹腔液CA125水平差异无显著性(P=0.18).腹腔液CA125水平明显高于血清CA125水平(P＜0.01),但二者无明显相关性(P＞0.50).腺肌病患者血清CA125水平受子宫大小、大体病理类型、使用性激素等因素影响.结论如用于子宫腺肌病的辅助诊断,血清CA125测定较腹腔液CA125测定敏感.腹腔液中CA125的主要来源可能为腹膜上皮细胞.     

子宫内膜异位症患者血清和腹腔液中铁离子浓度的测定

目的通过测定子宫内膜异位症(EM)患者血清和腹腔液中铁离子浓度是否较正常人升高来了解其与EM的关系及其在引起不孕机制中的作用.方法EM患者48例及对照组15例的血清和腹腔液,运用铬天青S的方法测定铁离子浓度.结果血清和腹腔液中铁离子浓度在EM患者Ⅲ～Ⅳ期中较Ⅰ～Ⅱ期及对照组明显升高,且两者间呈正相关;在EM各期曾受孕与不孕组间无明显差异.结论EM患者病情严重程度与血清和腹腔液中铁离子浓度高低呈正相关,在临床工作中可通过测定血清中铁离子浓度来进行粗略分期,从而有利于治疗方法的选择,简便易行.EM中铁离子与不孕间无明显因果关系.     

CA125与子宫内膜异位症的关系

ＣＡ１２５是一种血清抗原，普遍认为是上皮性卵巢癌的肿瘤标志物，８０年代中后期发现它与子人膜异位症也密切相关。子宫内膜异位病患者血清ＣＡ１２５水平较正常妇女高，在Ⅲ－Ⅳ期患者差异更大。对诊断子宫内膜异位症有一定价值。     

血清CA19-9及CA125测定诊断子宫内膜异位症

目的:探讨血清CA19-9及CA125测定对子宫内膜异位症(EMs)的诊断价值。方法:采用放射免疫法测定55例EMs患者血清CA19-9及CA125水平,并与同期门诊健康妇女(对照组)进行比较。结果:EMs组及对照组血清CA19-9和CA125检测值的中位数及阳性率分别为27.81 U/mL、43.6%,11.78 U/mL、0和24.2 U/mL、36.3%,9.02 U/mL、4.0%。两组间差异均有统计学意义(均P<0.05)。中重度(Ⅲ～Ⅳ期)EMs患者与轻度(Ⅰ～Ⅱ期)患者血清CA19-9和CA125中位数和阳性率分别为42.38 U/mL、57.9%,17.36 U/mL、11.8%和34.75 U/mL、50.0%,15.3U/mL、5.9%,不同分期间差异有统计学意义(均P<0.05)。血清CA19-9和CA125诊断EMs的敏感度、特异度及准确度分别为43.6%、100%、61.25%及36.3%、96.0%、55.0%。结论:血清CA125和CA19-9在EMs患者中均有明显升高,测定两种血清标记物水平可协助EMs的诊断;两者血清水平与EMs患者病情程度有关。     

动态监测CA125 EMAb对子宫动脉栓塞术治疗子宫腺肌病的疗效评价

目的采用血清CA125、子宫内膜抗体(EMAb)动态监测,评价子宫动脉栓塞术(UAE)治疗子宫腺肌病的疗效.方法 2002年3月至2004年3月对就诊于广州市妇婴医院、中山大学附属第三医院的86例确诊为子宫腺肌病患者,在UAE术前及术后连续动态监测血清CA125、EMAb之变化.结果血清CA125水平在UAE后第4周开始下降至(89±11.3)kU/L,和术前(128±44.3)kU/L比较,差异有显著性意义(P<0.05);术后CA125稳定下降,至18个月降至正常水平(<35kU/L);血清EMAb术前52例阳性,第2个月开始下降,和术前比较术后EMAb阳性率差异有显著性意义(P<0.05).结论血清CA125、EMAb动态监测UAE治疗子宫腺肌病的疗效,其方法简单且具有临床实用意义.     

子宫内膜异位症与血清CAl25水平相关分析

目的：探讨血清CAl25与子宫内膜异位症（EMs）的相关性。方法：对256例EMs患者进行回顾性分析。观察cAl25与EMs分型、rAFS分期、痛经程度、子宫直肠窝封闭情况的关系。结果：①腹膜型EMs血清CAl25水平显著低于卵巢型和混合型,卵巢型、混合型间差异无统计学意义：②不同临床分期间血清CAl25差异均有统计学意义,期别越高血清CAl25水平越高;③无痛经纽血清CAl25（19．5KU／L）水平低于有痛经组（轻度：28．3kU／L、中度：35．2kU／L、重度：35．0kU／L）,差异有统计学意义,不同程度痛经组间血清CAl25水平相当,差异无统计学意义;④子宫直肠窝无封闭组血清CAl25水平显著低于部分或全部封闭组,差异有统计学意义,部分和全部封闭组血清CAl25水平相当,差异无统计学意义;⑤各组间CAl25的阳性率均有显著差异;⑥多因素非条件Logistic分析结果提示rAFS分期是血清CAl25阳性的危险因素,分期越高血清CAl25阳性的发生风险越高。结论：血清CAl25对EMs病情严重程度的综合评估有重要意义,可用于协助判断EMs分型,临床上尤可用于EMs术前评价,为个体化术前处理提供参考。     

Serum CA 125 levels and survival in advanced ovarian cancer

We made a retrospective analysis of 85 patients with elevated serum CA 125 after surgery for ovarian cancer. Absolute CA 125 serum levels were a poor guide to prognosis. However, the ratio between the serum CA 125 after the first, second, or third course of treatment and the postoperative value was an excellent guide to prognosis. These were also independent and stable in the Cox Regression analysis.     

Ovarian Thecoma Associated with a Large Quantity of Ascites and Elevated Serum CA 125 and CA 15-3

Background: Elevation of tumour marker CA (cancer antigen) 125 associated with Meigs’ or atypical Meigs’ syndrome is widely recognized. Other tumour markers are available to assist in distinguishing between benign and malignant ovarian masses in the preoperative diagnosis.Case presentation: A 57-year-old woman presented with a suspicious pelvic mass and abundant ascites. Preoperative tumour markers CA 125 and CA 15-3 were elevated at 1750 U/mL and 60 U/mL, respectively. The woman underwent surgery, and 9 L of straw-coloured ascites were drained along with a solid-cystic ovarian mass. The final pathology disclosed an ovarian thecoma. Six months later, both tumour markers were normal.Conclusion: This first report of 2 elevated tumour markers associated with atypical Meigs’ syndrome cautions us not to rely on tumour markers to differentiate benign from malignant masses.     

超声联合CA125对卵巢恶性肿瘤的诊断价值

目的：探讨超声和肿瘤免疫标记物CA_(125)联合诊断卵巢恶性肿瘤的价值。方法：对139例卵巢肿瘤患者,其中恶性45例,良性94例,分别经腹及经阴道超声观察二维图像,并进行彩色及频谱多普勒检查,记录阻力指数。同时用放射免疫法测定患者血清CA_(125)。分别对卵巢肿瘤进行良恶性的判定,并与术后病理进行对照。结果：二维超声及肿瘤标记物CA_(125)联合应用诊断卵巢恶性肿瘤的敏感性及特异性高于单独的任何一种方法。结论：二维超声及肿瘤标记物CA_(125)联合应用对诊断卵巢恶性肿瘤有一定的价值。     

Serum CA 125 levels before, during and after treatment for endometriosis

Objectives: The aim of this study was to assess the treatment of endometriosis with a gonadotropin-releasing hormone (GnRH) agonist in terms of changes to the extent of disease and to CA 125 levels as well as to recurrence during follow-up. Methods: The levels of serum CA 125 were evaluated in 66 patients with endometriosis diagnosed and staged by laparoscopy according to the revised American Fertility Society classification, who received a 6-month course of a GnRH agonist. Serum CA 125 levels were measured before, during (3 and 6 months after the initiation of therapy) and 6 months after cessation of therapy. Results: Patients with minimal and mild endometriosis had significantly higher mean pretreatment values than control subjects in the luteal phase of the cycle or than postmenopausal women (P < 0.05), but the overall mean value was still below 35 U/ml. Levels of CA 125 fell during treatment to those found in normal controls, but rose again after the end of treatment. The sensitivity and specificity of CA 125 were 75% and 83.3%, respectively, and its positive predictive value as a marker of recurrence was 46.36%. Conclusion: These data suggest that CA 125 may be a reliable indicator for monitoring the efficacy of GnRH agonist treatment of endometriosis, but its value as a predictor of recurrence is low, probably due to the suppression of all CA 125 sources such as endometrium, ovaries and implants.     

Tumor tissue CA125 in ovarian carcinoma patients with normal serum levels

A good correlation between elevated serum CA125 and its immunolocalization in ovarian tumor tissue has been reported. This study was undertaken in order to assess the presence of CA125 in tumor tissue obtained from ovarian carcinoma patients with normal serum levels. Eleven such ovarian carcinoma patients (nine of them serous) were identified. In seven the level was normal prior to the initial operation, and in four, prior to a positive second-look operation. Immunohistochemical staining of paraffin sections for CA125 was positive in seven of the tumor tissue samples. Tumor tissue of most ovarian carcinoma patients with a preoperative normal serum CA125 contains the antigen, but an undetermined mechanism prevents elevated serum levels.     

Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies

Serum CA 125 levels were evaluated in 26 patients with fallopian tube malignancies. CA 125 was elevated preoperatively in seven samples (median 178 U ml⁻¹ range 41–19021 U ml⁻¹), and postoperatively in eight of nine (89%) samples collected from patients with residual disease (median 109 U ml⁻¹ range 10–1883 U ml⁻¹) but only in one of seven (14%) samples from patients without residual disease (median 14, range 5–170 U ml⁻¹) ( P < 0.001). Changes in the serum CA 125 level during chemotherapy correlated with the clinical course of disease in 13 of 14 patients with a pre-chemotherapy serum CA 125 level> 35 U ml⁻¹. Nine patients with clinical remissions showed decreasing serum CA 125 levels, one with clinically stable disease showed decreasing levels and four with disease progression showed increasing levels. Serum CA 125 levels were measured in four patients before second-look laparotomy. Two of three with positive findings at laparotomy had elevated serum CA 125 levels whilst the third had a normal level. One patient with negative findings at second-look surgery had a normal CA 125 level. Disease relapse was associated with elevated serum CA 125 levels in nine of 10 patients (median 108 U ml⁻¹, range 27–38200 U ml⁻¹). Using immunohistochemical staining, none of the tumors showed positive cytoplasmic staining for c-erbB-2 (NEU) oncogene. This report shows that CA 125 is a reliable tumor marker for monitoring patients with cancer of the fallopian tube during active treatment and follow-up.